Phase II study of nab-paclitaxel with gemcitabine for relapsed/refractory small cell lung cancer

Overview of attention for article published in Frontiers in oncology, July 2024

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (59th percentile)
High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

twitter: 3 X users

reddit: 1 Redditor

Readers on

mendeley: 1 Mendeley

Summary X Reddit

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 8,511 followers.

RT @pharma_jonpi: Los Tratamientos Para el #SMALL_CELL_LUNG_CÁNCER SEGUNDA LÍNEA, Como #LURBINECTEDIN y #TOPOTECAN, están Limitados Por una…

16 Aug 2024

Reply Repost Favourite

Los Tratamientos Para el #SMALL_CELL_LUNG_CÁNCER SEGUNDA LÍNEA, Como #LURBINECTEDIN y #TOPOTECAN, están Limitados Por una Eficacia Modesta y Eventos Adversos Hematológicos Significativos, lo Que Deja la Necesidad de Nuevos Agentes Terapéuticos. https://t.

16 Aug 2024

Reply Repost Favourite

New Research: Phase II study of nab-paclitaxel with gemcitabine for relapsed/refractory small cell lung cancer https://t.co/e7tmkjHVEe #FrontiersIn #Oncology

31 Jul 2024

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.